AtriCure Inc. (ATRC)
| Bid | 31.99 |
| Market Cap | 1.6B |
| Revenue (ttm) | 465.31M |
| Net Income (ttm) | -44.7M |
| EPS (ttm) | -0.95 |
| PE Ratio (ttm) | -34.13 |
| Forward PE | -67.66 |
| Analyst | Buy |
| Ask | 32.78 |
| Volume | 123,490 |
| Avg. Volume (20D) | 590,840 |
| Open | 32.66 |
| Previous Close | 32.07 |
| Day's Range | 32.10 - 32.82 |
| 52-Week Range | 18.94 - 43.11 |
| Beta | 1.65 |
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform tem...
Analyst Forecast
According to 10 analyst ratings, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is $50.5, which is an increase of 55.77% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial ResultsMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op...
2 months ago · businesswire.com
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial ResultsMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o...